Schriber J R, Dejbakhsh-Jones S, Kusnierz-Glaz C R, Ginzton N, Still B, Negrin R S, Greenberg P, Strober S
Division of Immunology and Rheumatology, Stanford University Medical School, CA 94305-5111, USA.
Exp Hematol. 1995 Aug;23(9):1024-9.
We have evaluated the use of iso-osmolar Percoll density gradients to enrich CD34+ hematopoietic progenitor cells and to reduce T cells for purposes of bone marrow or mobilized peripheral blood cell transplantation (BMT or PBCT). Samples from 12 normal BM donors and 11 patients undergoing mobilization of PB cells using chemotherapy and G-CSF were placed over a five-step density gradient from 40 to 50% Percoll. In BM, low-density fractions 1 to 3 (40 to 45% Percoll) accounted for 3% of starting nucleated cells with a 10- to 20-fold enrichment of hematopoietic progenitors (CD34+ cells) and a 20-fold reduction of CD4+ and CD8+ T cells. In PB, fractions 1 to 3 accounted for 20 to 30% of the starting nucleated cells with a five-fold enrichment of hematopoietic progenitors. Based on these values, such populations have been used for clinical transplantation using a single apheresis. The reduced cell numbers in the low-density fractions can facilitate tumor purging, and the reduced T cell numbers present in the marrow may ameliorate graft-vs.-host disease.
我们评估了使用等渗Percoll密度梯度来富集CD34+造血祖细胞并减少T细胞，以用于骨髓或动员外周血细胞移植（BMT或PBCT）的目的。从12名正常骨髓供体和11名使用化疗和G-CSF动员外周血干细胞的患者采集的样本，被置于一个从40%到50% Percoll的五步密度梯度上。在骨髓中，低密度组分1至3（40%至45% Percoll）占起始有核细胞的3%，造血祖细胞（CD34+细胞）富集了10至20倍，CD4+和CD8+ T细胞减少了20倍。在外周血中，组分1至3占起始有核细胞的20%至30%，造血祖细胞富集了5倍。基于这些数值，此类细胞群体已被用于单次采集的临床移植。低密度组分中细胞数量的减少有助于肿瘤清除，骨髓中T细胞数量的减少可能会改善移植物抗宿主病。
